← Back to Search

Antiprotozoal Agent

Atovaquone for Ovarian Cancer

Phase 2
Recruiting
Led By Namita Khanna, MD, MSPH
Research Sponsored by Emory University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from initiation of atovaquone to progression or death, assessed up to 1 year
Awards & highlights
No Placebo-Only Group

Summary

This trial tests if repurposed atovaquone can treat ovarian cancer better than existing treatments. It works by stopping the growth of protozoa that cause pneumonia.

Who is the study for?
This trial is for adults with high-grade serous ovarian cancer that has worsened within six months after platinum-based chemotherapy. Participants must be in good physical condition (ECOG status of 0 or 1) and can have had any number of prior treatments. The study welcomes non-English speakers and referrals from community practices.
What is being tested?
The trial is evaluating the effectiveness of Atovaquone, an antiprotozoal medication typically used to prevent pneumonia, as a new treatment option for patients with platinum-resistant ovarian cancer. It involves procedures like paracentesis, biopsy, and CT scans to monitor the disease's response.
What are the potential side effects?
Atovaquone may cause side effects such as digestive issues (nausea, vomiting), rash, fever, insomnia, coughing and diarrhea. More serious but less common side effects include liver problems and allergic reactions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from initiation of atovaquone to progression or death, assessed up to 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and from initiation of atovaquone to progression or death, assessed up to 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Progression free survival (PFS)
Secondary study objectives
Clinical benefit rate
Incidence of adverse events
Overall survival (OS)

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Treatment (atovaquone)Experimental Treatment4 Interventions
Patients receive atovaquone PO on study. Patients also undergo CT and biopsy or paracentesis throughout the study.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Atovaquone
2012
Completed Phase 1
~80
Computed Tomography
2017
Completed Phase 2
~2790
Biopsy
2014
Completed Phase 4
~1150
Paracentesis
2005
N/A
~80

Find a Location

Who is running the clinical trial?

Emory UniversityLead Sponsor
1,708 Previous Clinical Trials
2,607,456 Total Patients Enrolled
3 Trials studying Ovarian Cancer
2,402 Patients Enrolled for Ovarian Cancer
National Cancer Institute (NCI)NIH
13,958 Previous Clinical Trials
41,112,552 Total Patients Enrolled
290 Trials studying Ovarian Cancer
76,723 Patients Enrolled for Ovarian Cancer
Namita Khanna, MD, MSPHPrincipal InvestigatorEmory University Hospital/Winship Cancer Institute

Media Library

Atovaquone (Antiprotozoal Agent) Clinical Trial Eligibility Overview. Trial Name: NCT05998135 — Phase 2
Ovarian Cancer Research Study Groups: Treatment (atovaquone)
Ovarian Cancer Clinical Trial 2023: Atovaquone Highlights & Side Effects. Trial Name: NCT05998135 — Phase 2
Atovaquone (Antiprotozoal Agent) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05998135 — Phase 2
~7 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top